Treatment of Visceral (Internal) Shingles in Adults
For visceral herpes zoster, initiate intravenous acyclovir immediately and reduce immunosuppressive medications if the patient is immunocompromised. This represents the standard of care for disseminated or internal organ involvement with varicella-zoster virus.
Treatment Algorithm
Immediate Management
Start IV acyclovir without delay when visceral zoster is suspected in any patient presenting with unexplained hepatitis, pancreatitis, gastritis, or abdominal pain who has herpes zoster or is immunocompromised 1, 2. The kidney transplant guideline explicitly recommends intravenous acyclovir for disseminated or invasive herpes zoster 1.
Immunosuppression Adjustment
Temporarily reduce or cease immunosuppressive medications in patients with systemic or visceral involvement 1. This is a strong recommendation (1C grade) that applies to all immunocompromised patients with disseminated disease.
Duration of Therapy
- Continue IV acyclovir until clinical response is achieved 1
- Then switch to oral antiviral (acyclovir, valacyclovir, or famciclovir) to complete 14-21 days total treatment 1
- For disseminated disease, continue treatment at least until all lesions have scabbed 1
Key Clinical Considerations
High index of suspicion is critical: Visceral zoster can present without cutaneous manifestations initially 2. In immunocompromised patients with herpes zoster who develop unexplained organ dysfunction (liver, pancreas, gastrointestinal), assume visceral dissemination until proven otherwise.
Immunohistochemical staining of tissue biopsy specimens allows rapid diagnosis when visceral involvement is suspected 2. This can be performed on routine paraffin-embedded specimens.
Common Pitfalls to Avoid
- Do not wait for skin lesions to appear before treating suspected visceral zoster in immunocompromised patients—internal organs may be affected before or without cutaneous involvement 2
- Do not use oral antivirals alone for visceral/disseminated disease—IV acyclovir is required 1
- Do not continue full immunosuppression during active disseminated infection—temporary reduction is necessary for immune recovery 1
The evidence strongly supports aggressive early treatment with IV acyclovir as the cornerstone of therapy, particularly given the potential for serious morbidity and mortality from visceral organ involvement in immunocompromised hosts 1, 2.